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Abstract
Background: Endothelial progenitor cells (EPCs) play an important role in vascular repair and a decrease in the
number of EPCs is observed in type 2 diabetes. However, there is no report on the change of EPCs after glycemic
control. This study therefore aimed to investigate the EPC number and function in patients with good and poor
glycemic control.
Methods: The number of EPCs was studied using flow cytometry by co-expression of CD34 and VEGFR2. The EPCs
were cultured and characterized by the expression of UEA-I, CD34, VEGFR2, vWF and Dil-Ac-LDL engulfment, as
well as the ability to form capillary-like structures. An in vitro study on the effect of hyperglycemia on the
proliferation and viability of the cultured EPCs was also performed.
Results: The number of EPCs in type 2 diabetes was significantly decreased compared with healthy controls and
there was an inverse correlation between the EPC numbers and plasma glucose, as well as HbA1C. The number
and function of EPCs in patients with good glycemic control were recovered compared with those with poor
glycemic control. When glucose was supplemented in the culture in vitro, there was a negative effect on the
proliferation and viability of EPCs, in a dose-dependent manner, whereas the enhancement of apoptosis was
observed.
Conclusion: There was EPC dysfunction in type 2 diabetes which might be improved by strict glycemic control.
However, the circulating EPC number and proliferative function in patients with good glycemic control did not
reach the level in healthy controls.
Background
Regeneration and reconstruction of the vascular
endothelium is essential in vascular repair processes.
This endothelial reconstruction can be accomplished by
the proliferation and migration of surrounding mature
endothelial cells [1,2]. However, mature endothelial cells
are terminally differentiated cells with low proliferative
potential, and their capacity to repair damaged vessels is
limited [3,4]. Recent studies reveal that endothelial pro-
genitor cells (EPCs) which reside in the bone marrow
and to some extent in peripheral blood [5,6], play an
important role in angiogenesis through their capacity to
proliferate, migrate, differentiate and as a source of
paracrine factors for pro-angiogenic cytokines [7,8].
These EPCs co-express surface markers of both hemato-
poietic stem cells (CD34 and CD133) and endothelial
cells (CD146, vWF and VEGFR2, also known as KDR)
[9,10].
Previous reports show that the number of circulating
EPCs is decreased in both type 1 and type 2 diabetes
which is likely to be involved in the pathogenesis of vas-
cular complications [11-13]. These complications can be
observed clinically, even in diabetics who achieve good
long-term glycemic control [14]. It is therefore possible
that there is still EPC dysfunction in diabetics with good
glycemic control. We studied the number of the circu-
lating EPCs in patients with type 2 diabetes as divided
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study the effect of glycemic control. A quantitative
assessment of circulating EPCs was made by using flow
cytometry. In vitro hyperglycemic effect using various
glucose concentrations on the viability, proliferation and
apoptosis of cultured EPCs from both diabetic patients
and healthy controls were also performed.
Methods
Subjects
The study was approved by the Ethical Committee and is
in accordance with the Helsinki Declaration of 1975. All
subjects in the study had given written informed consent
prior to participating. The study enrolled 36 patients
with type 2 diabetes who attended the diabetic clinic dur-
ing the period from May to August 2007. Fourteen were
male and 22 were female. The ages ranged from 31-86
years (mean 61.5 ± 13.2 years) and the duration of dia-
betes varied from 1-15 years (mean 6.2 ± 4.3 years). Clin-
ical history and medications were evaluated together with
fasting blood sugar (FBS) and glycosylated hemoglobin
(HbA1C). Patients were divided into two groups accord-
ing to criteria established by the American Diabetic Asso-
ciation (ADA) [15]; the first group had good glycemic
control (FBS ≤ 7.0 mmol/l and HbA1C ≤ 7.0%) and the
second group had poor glycemic control (FBS > 7.0
mmol/l and HbA1C > 7.0%). Patients with coronary
artery disease, cerebrovascular disease, peripheral vascu-
lar disease, chronic inflammation and malignant disease
were excluded. There were no significant differences in
age, body mass index (BMI), duration of diabetes, blood
pressure and lipid profiles, between diabetic patients with
good and poor glycemic control (Table 1).
Twenty healthy medical personnel served as controls.
Of these, 5 were male and 15 were female. The ages
ranged from 39-83 years (mean 58.1 ± 11.3 years). All
controls had no clinical history of diabetes or hyperlipi-
demia, and had normal FBS of < 7 mmol/l. They had
normal physical examination and had not received any
medication.
Isolation and quantification of circulating EPCs
Twenty ml of heparinized blood was used to isolate and
quantify the circulating EPCs. Briefly, mononuclear cells
(MNCs) were isolated using Ficoll-Paque (Amersham
Bioscience, USA) density gradient centrifugation (400 g,
20°C, 20 minutes), then washed twice with phosphate
buffered saline (PBS), counted, and resuspended in PBS.
Quantification of circulating EPCs was performed by
flow cytometry as previously described [16]. Briefly, 1 ×
10
6 MNCs were incubated with a combination of a
FITC-conjugated anti-human CD34 antibody (BD Bios-
ciences, USA) and a PE-conjugated anti-human
VEGFR2 antibody (R&D Systems, USA) for 15 minutes
at 4°C in the dark. Cell pellets were washed twice with
PBS and fixed with 2% (v/v) paraformaldehyde in PBS.
T h ep r e p a r a t i o n sw e r ek e p ta t4 ° Ci nt h ed a r k .F l o w
cytometry analysis was performed using a FACScalibur™
flow cytometer (Becton Dickinson, USA) and the Cell-
Quest® FACs software.
Culture and characterization of circulating EPCs
One million MNCs were resuspended in endothelial cell
growth medium [endothelial basal medium-2 (EBM-2)
(Clonetics; Walkersville, USA), supplemented with EGM-
2 single aliquots containing 2% (v/v) fetal bovine serum,
5 μg/ml epidermal growth factor, 200 μg/ml hydrocorti-
sone, 0.5 μg/ml vascular endothelial growth factor, 10
μg/ml basic fibroblast growth factor, 20 μg/ml long R3
insulin-like growth factor 1, and 1 mg/ml ascorbic acid].
They were then plated in a T-25 culture flask coated with
10 μg/ml human fibronectin (Amersham Biosciences,
USA) and after culture for 3 days, non-adherent cells
were removed and fresh medium was added. Thereafter,
the medium was replaced every 3 days for the entire cul-
ture period. Identification of EPCs was performed by
staining with 1,1-dioctadecyl-3,3,3,3-tetramethylindocar-
bocyanine-labeled Ac-LDL (Dil-Ac-LDL) and FITC-con-
jugated Ulex europaeus agglutinin-I (UEA-I) as described
previously [7,16]. Briefly, cells were cultured on cover-
slips coated with 10 μg/ml human fibronectin (Amer-
sham Biosciences, USA). At the required time points,
medium was removed from plates and the adherent cells
on coverslips were incubated with 10 μg/ml Dil-Ac-LDL
(Bio Technologies, USA) at 37°C for 4 hours. The cells
were then washed three times with PBS, fixed with 2%
(v/v) paraformaldehyde in PBS, incubated with 200 μL
mouse anti-human UEA-I antibody-conjugated with
FITC (Sigma, USA) at 4°C for 1 hours, and then washed
three times with PBS. All slides were kept in a light-tight
box and examined by fluorescence microscopy.
T h ec u l t u r e dE P C sw e r ea l s oi n c u b a t e dw i t haF I T C -
conjugated anti-human CD34 antibody (BD Biosciences,
USA), a PE-conjugated anti-human VEGFR2 antibody
(R&D Systems, USA), a FITC-conjugated anti-human
CD146 antibody (BD Biosciences, USA), and a FITC-
conjugated anti-human vWF antibody (R&D Systems,
USA) for 15 minutes at 4°C in the dark. Cell pellets
were washed twice with PBS and fixed with 2% (v/v)
paraformaldehyde in PBS. The preparations were kept at
4°C in the dark. Flow cytometry analysis was performed
using a FACScalibur™ flow cytometer (Becton Dickinson,
USA) and the CellQuest® FACs software.
Formation of capillary-like structures on Matrigel
Twenty-four well plates were coated with 500 μLo f
Matrigel (BD Biosciences, USA) and 4 × 10
4 EPCs were
added to each well. The plates were incubated for 24
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to form capillary-like structures.
In vitro studies on the effects of hyperglycemia on
cultured EPCs
The effects of various glucose concentrations on cultured
EPCs from both diabetic patients and healthy controls
were studied for viability, proliferation, and apoptosis.
Passage four EPCs were used as target cells. Cells samples
were cultured in endothelial cell growth medium supple-
mented with various concentrations of D-glucose at final
concentrations of 7.8, 10.5, 13.5, 16.5 and 19.5 mmol/l.
(a) Effect on viability
Viability of cells was studied using trypan blue stain-
ing after 21 days of culture. Cultured cells from each
treatment group were trypsinized and the number of
viable cells was counted using a hemacytometer. The
results were compared with controls of EPCs cul-
tured in 5.5 mmol/l of D-glucose.
(b) Effect on proliferative function
The influence of increasing concentrations of glu-
cose on the proliferative capability of cultured EPCs
was assessed using the colorimetric MTT [3-(4,5-
dimethylthiazol-2-yl) K2,5-diphenyl tetrazolium bro-
mide] proliferation assay (Sigma, USA) [17]. Briefly,
1×1 0
4 cultured EPCs were seeded into each well of
a9 6 - w e l lp l a t ec o n t a i n i n g1 0 0μl endothelial cell
growth medium. Cell samples were then exposed to
various concentrations of D-glucose as described
previously. After 7, 14 and 21 days of continuous
exposure, 1 mg/ml of MTT reagent was added to
each well and the cells were incubated for another 4
hours at 37°C. The absorbance was measured at 595
nm using a spectrophotometer. The data were pre-
sented as a percent of proliferative inhibition, which
was calculated by the following formula:
% proliferative inhibition
1O D EPCs in hyperglycemic condi

 t tion EPCs in normal condition at the same time point /OD  
 

 100
(c) Effect on apoptosis
The percentage of apoptotic cells was studied by
flow cytometry using a 7-AAD/annexin V apoptosis
detection kit (BD Biosciences, USA) [18]. Briefly, 2 ×
10
5 cultured EPCs were seeded into each well of a
24-well plate containing 1 ml endothelial cell growth
medium. Cell samples were then exposed to various
concentrations of D-glucose as previously described.
After culture for 7 and 14 days, the cells were har-
vested and washed twice with PBS. They were then
resuspended in binding buffer, supplemented with 5
μl annexin V and 5 μL 7-AAD, at 2 × 10
5 cells/100
μl binding buffer and incubated at room temperature
for 15 minutes in the dark. Flow cytometry analysis
was performed using a FACScalibur™ (Becton Dick-
inson, USA) and CellQuest® FACs software.
Table 1 Baseline characteristics of patients with type 2 diabetes as divided into poor and good glycemic control
Poor glycemic control Good glycemic control P value
Number 23 13 -
Age (years) 59.7 ± 13.2 (31-86) 64.7 ± 13.2 (41-86) 0.287
Sex (male:female) 9:14 5:08 -
BMI (kg/m
2) 23.8 ± 2.8 21.6 ± 4.5 0.516
Duration of diabetes (years) 6.7 ± 4.3 (1-15) 5.2 ± 4.3 (1-13.4) 0.433
Systolic blood pressure (mmHg) 126.2 ± 18 (100-170) 134.4 ± 16 (110-150) 0.251
Diastolic blood pressure (mmHg) 79.1 ± 8.9 (60-90) 76.7 ± 7.1 (70-90) 0.582
HbA1C (%) 9.2 ± 1.4 (7-12.2) 6.2 ± 0.5 (5.3-6.6) < 0.001
FBS (mmol/l) 8.9 ± 1.8 (5.8-11.8) 6.7 ± 0.8 (5.6-8.2) < 0.001
Total cholesterol (mg/dl) 175.9 ± 31.9 (134-242) 191.8 ± 42.6 (148-264) 0.314
LDL cholesterol (mg/dl) 98.6 ± 25.3 (61-146) 125 ± 41.9 (76-215) 0.936
HDL cholesterol (mg/dl) 51.8 ± 12.8 (35-75) 48 ± 13.6 (32-73) 0.977
Triglyceride (mg/dl) 137.8 ± 70 (54-310) 218.5 ± 121.5 (100-340) 0.124
Therapy
Statin [n (%)] 15 (65) 7 (53) -
ACEI/ARB [n (%)] 4 (17) 3 (23) -
Aspirin [n (%)] 1 (4) 1 (7) -
OHA [n (%)] 20 (87) 10 (77) -
Insulin [n (%)] 1 (4) 1 (7) -
OHD + Insulin [n (%)] 2 (8) - -
Data are presented as mean ± SD, percentage or median (interquartile range); ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blockers; BMI, body-mass index; FBS, fasting blood sugar; HbA1C, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OHA, oral
hypoglycemic agent.
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Data are presented as mean ± SD or mean ± SEM as
indicated. For comparison, unpaired Student t-tests or
ANOVA tests were used. The relationship was calcu-
lated using Spearman’s correlation coefficient. A P value
of < 0.05 was considered to be statistically significant.
Results
Number of circulating EPCs
The numbers of circulating EPCs, as determined by co-
expression of the two EPC markers, CD34 and VEGFR2,
and quantified using flow cytometry, are shown in Fig.
1a-b. Fig. 1c illustrates absolute number of circulating
EPCs in diabetic patients in comparison with those in
h e a l t h yc o n t r o l s .T h ea b s o l u t en u m b e ro fc i r c u l a t i n g
EPCs was significantly lower in diabetic patients com-
pared with healthy controls (8.6 × 10
6 ± 5.9 × 10
6 vs. 23
×1 0
6 ±2 . 3×1 0
6, P < 0.001). Notably, the absolute
number of circulating EPCs in diabetic patients with
good glycemic control was significantly higher than that
of poor glycemic control (15.6 × 10
6 ±1 . 6×1 0
6 vs. 5.5
×1 0
6 ± 0.5 × 10
6, P < 0.001), but still significantly lower
than healthy controls (15.6 × 10
6 ±1 . 6×1 0
6 vs. 23 ×
10
6 ± 2.3 × 10
6, P < 0.001) (Fig. 1d). In diabetic patients,
Spearman’s correlation analysis revealed that the num-
bers of circulating EPCs were inversely correlated with
the concentrations of both fasting blood sugar (r =
-0.52, P <0 . 0 5 )a n dH b A 1 C (r = -0.40, P <0 . 0 5 )( F i g .
1e, f).
Characterization of cultured EPCs
Following the culture of MNCs in endothelial cell
growth medium for at least 3 weeks, the EPC colonies
were observed. Those isolated from both diabetic
patients and healthy controls displayed a similar mor-
phology, being spindle-shaped cells with a low nuclear/
cytoplasmic ratio (Fig. 2a). EPCs isolated from both
sources also displayed characteristic EPC phenotypes by
uptaking Dil-Ac-LDL (Fig. 2a), expressing UEA-I (Fig.
2a), CD34, vWF, CD146 and VEGFR2 on the plasma
membrane (Fig. 2b), as well as the ability to form capil-
lary-like structures on Matrigel (Fig 2c). However, cul-
ture of MNCs from diabetic patients took a significantly
longer period of time to form colonies with cobblestone
appearance (EPC-like colonies) than healthy controls
(30.8 ± 3.9 days vs. 22.4 ± 2.7 days, P < 0.05).
In vitro study on the effect of hyperglycemia on cultured
EPCs
(a) Effect on viability
The effects of hyperglycemia on EPC viability were
studied by exposing cultured EPCs to various con-
centrations of D-glucose for 21 days as shown in
Fig. 3a,b. The number of cultured EPCs in high
glucose concentrations (13.5, 16.5 and 19.5 mmol/l)
was significantly reduced compared with controls
(EPCs cultured in 5.5 mmol/l of D-glucose) (P <
0.05), and in a dose-dependent manner.
(b) Effect on proliferative function
The effects of hyperglycemia on proliferative func-
tion of EPCs determined by a MTT assay are shown
in Fig. 3c,d. The proliferation of cultured EPCs from
both diabetic patients and healthy controls decreased
steadily in a dose- and time-dependent manner in
response to increasing concentrations of glucose.
The proliferation of cultured EPCs was significantly
inhibited even in the glucose concentration corre-
sponding to the diabetes with good glycemic control
(7.8 mmol/l), compared with controls (EPCs cultured
in 5.5 mmol/l of D-glucose) (Fig. 3c,d) (P <0 . 0 5 ) .
These findings indicate that hyperglycemia had a
negative effect on the proliferative capacity of EPCs
in a dose-dependent and time-dependent manner.
(c) Effect on apoptosis
The effects of hyperglycemia on apoptosis of EPCs
were determined using flow cytometry, as shown in
Fig. 4a-d. The apoptotic rates of cultured EPCs were
significantly increased with high glucose concentra-
tions in a dose- and time-dependent manner com-
pared with controls (EPCs cultured in 5.5 mmol/l of
D-glucose) (Fig. 4e,f). At a glucose concentration of
7.8 mmol/l, the EPC apoptotic rate was still
increased compared with controls (Fig. 4e,f). There
were no viable cultured EPCs from diabetic patients
after 14 days of culture, so the apoptotic rate could
not be studied (Fig. 4f).
Discussion
Previous attempts to culture EPCs gave rise to highly
variable results due, primarily to divergent culture con-
ditions [11,19-21], and in addition, the absolute number
of EPCs could not be quantified due to the lack of EPC-
related cell markers. Recently, the identification and
quantification of circulating EPCs using antibodies
against EPC-related cell surface antigens and flow cyto-
metric analysis have been developed [22]. This metho-
dology is not only more sensitive and specific but also
makes possible the quantification of circulating EPCs.
However, even with the advent of this new technology,
there have been only a few reports using this methodol-
ogy to identify and quantify the number of circulating
EPCs in diabetic patients [22-24].
A reduction in EPC number is likely to influence vas-
cular integrity as it was reported that the EPC number
is a surrogate marker for vascular function and cumula-
tive cardiovascular risk in healthy persons [6,19,25-28].
In diabetic patients with vascular complications, there
was a marked reduction of circulating EPCs compared
Churdchomjan et al. BMC Endocrine Disorders 2010, 10:5
http://www.biomedcentral.com/1472-6823/10/5
Page 4 of 10Figure 1 Circulating EPC number in healthy controls and diabetes. a and b: Circulating EPC numbers were determined by flow cytometry
for the co-expression of CD34 and VEGFR2 (b). Peripheral blood MNCs incubated with IgG isotype control (a) serve as a negative control to
determine the intrinsic fluorescent intensity of the peripheral blood MNCs and to define positive area R2. c: Absolute number of circulating EPCs
in healthy controls and diabetes as determined by the co-expression of CD34 and VEGFR2. d: Absolute number of circulating EPCs in healthy
controls, diabetes with good and poor glycemic control as determined by the co-expression of CD34 and VEGFR2. e: Correlation between the
circulating EPC numbers and FBS, f: Correlation between the circulating EPC numbers and HbA1C, g: Absolute number of circulating CD34
+/VEGFR2- cells in healthy controls and diabetes. Data are presented as means ± SEM.
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correlated with the degree of severity of the vascular
complications [22]. Our observations that the EPC num-
bers were significantly higher in diabetic patients with
good glycemic control compared with those with poor
glycemic control, supports our hypothesis that the EPC
function can be improved by strict control of blood glu-
cose to a normal level, and thereby preventing or ameli-
orating the development of severe vascular
complications in diabetic patients.
A reduction of circulating EPCs in diabetic patients
may reflect a shortened peripheral survival of EPCs, or a
poor mobilization of EPCs from the bone marrow. Our
results show that the absolute number of circulating
CD34+ and EPC (CD34+/VEGFR2+) cells in diabetes
were significantly lower than healthy controls, whereas
the absolute number of CD34+/VEGFR2- in diabetic
patients was not different from healthy controls (0.767 ±
0.18 vs. 1.033 ± 0.27, p = 0.203) (Fig. 1g). Although this
finding suggests that there is a decreased survival of cir-
culating EPCs in diabetic patients, the possibility of poor
mobilization of EPCs from the bone marrow cannot be
excluded. Previous studies in a rat model of hindlimb
ischemia/reperfusion injury, showed that there was a
defective EPC mobilization from bone marrow in dia-
betic rats compared with controls [7]. Furthermore,
there was additional evidence in mice that endothelial
nitric oxide synthase (eNOS) activation is impaired in
diabetes resulting in poor mobilization of EPCs [29].
In vitro analysis of the effect of increased glucose con-
centration on cultured EPCs revealed that hyperglycemia
significantly decreased EPC viability and proliferation,
and increased apoptosis, in dose-dependent manners.
We used various concentrations of glucose ranging from
7.8 mmol/l (equivalent to FBS of 140 mg/dl) to 19.5
mmol/l (equivalent to FBS of 345 mg/dl) to simulate
hyperglycemia because these are more or less similar to
the conditions in diabetic patients, whereas previous stu-
dies had used a higher glucose concentration of 33
mmol/l [30-33]. Although D-glucose can increase osmo-
tic stress which may directly affect the EPCs, the pre-
vious studies showed that hyperosmolarity using both L-
glucose and mannitol had no effect on EPCs [34] indi-
cating that hyperosmolarity has no effect on EPCs.
The mechanism contributing to the reduction of cir-
culating EPCs in diabetes is still unknown, however, it
may be due to decreased proliferation and/or acceler-
ated cell death. Previous studies showed that exposure
to hyperglycemic conditions resulted in an accumulation
of EPCs in resting stage and decreased number of EPCs
in proliferative stage [34]. This finding indicated an up-
regulation of p16 and p21 involved in the regulation of
G1-S phase transition and a decreased number of prolif-
erating EPCs in hyperglycemia. Further studies have
shown that an altered expression level of p16 and p21 is
associated with apoptosis in several cell types [34-36]. In
addition, hyperglycemia can up-regulate the expression
of ETS transcription factor which plays an important
Figure 2 Characteristics of isolated EPCs from healthy controls and diabetes. a1 and a2: Phase contrast microscopic photos of
representative cultured EPCs (passage 2) isolated from MNCs of normal healthy controls (a1) and MNCs of diabetic patients (a2). a3 and a4:
Fluorescent microscopic photos of representative cultured EPCs isolated from MNCs of normal healthy controls (a3) and MNCs of diabetic
patients (a4). Red color (indicated by red arrows) represents fluorescent staining of DiI-Ac-LDL and green color (indicated by green arrows)
represents fluorescent staining of FITC-conjugated UEA-I. [Fig. a1 and a2, Magnification × 200; Fig. a3 and a4, Magnification × 400], b:
Representative histogram based on flow cytometric analysis immunolabelling with a control antibody (green line) and specific antibodies (blue
line) to EPC-related markers (CD146, CD34, VEGFR2 and CD146), c: EPCs from both healthy subjects and diabetic patients formed capillary-like
structure on Matrigel [Magnification × 40].
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ing in the blockade of the functional activity of EPCs
[37]. Moreover, increased oxidative stress, as shown by
increased production of free radicals and/or impaired
anti-oxidant defense capabilities, were reported in
patients with diabetes [38,39]. Also, there was a report
indicating a relationship between various disturbances in
mitochondrial function and diabetes [40]. However, the
EPCs are known to be relatively resistant to oxidative
stress than the mature endothelial cells [41]. It is still
uncertain that the presence of oxidative stress may con-
tribute to the impaired EPC function/proliferation in
high glucose status [42].
The reduced viability and proliferation of EPCs in the
hyperglycemic condition might also involve the phos-
phatidylinositol 3’-kinase (PI3k)/serine-threonine kinase
(Akt)/endothelial nitric oxide synthase (eNOS) pathway
[PI3k/Akt/eNOS]. Previous reports indicate that
activating the PI3k/Akt in endothelial cells can prevent
cell death [43], resulting in increasing cell survival and
activating eNOS which leads to NO production [44].
Recent studies show that the PI3k/Akt/eNOS pathway
plays an important role in preventing high glucose-
induced cell injury [45]. It is likely that hyperglycemia
inhibits the PI3k/Akt/eNOS pathway in EPCs, thus
resulting in our observed reduced viability and prolifera-
tion, with increased EPC apoptosis.
Our findings that the EPC number in patients with
good glycemic control was significantly higher than
those with poor glycemic control, and when more glu-
cose was added to EPC cultures in vitro, viability and
proliferation decreased whereas apoptosis increased,
indirectly supports the importance of strict control of
blood glucose in preventing vascular complications.
However, the observed circulating EPC number in
patients with good glycemic control did not reach the
Figure 3 Number and proliferative capacity of EPCs cultured in hyperglycemic conditions. a and b: Effect of various glucose
concentrations on the number of cultured EPCs isolated from healthy controls (a) and diabetes (b) after 21 days of culture. c and d: Effect of
various glucose concentrations on the proliferative capacity of cultured EPCs isolated from diabetes (c) and healthy controls (d) as determined
by MTT assay. * p < 0.05, † p < 0.01 versus control.
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Page 7 of 10Figure 4 Apoptotic rate of EPCs cultured in hyperglycemic conditions. a-d: Apoptotic EPCs as identified by flow cytometry with the
expression of annexin V and 7-AAD. e and f: Effect of various glucose concentrations on the apoptotic rate of cultured EPCs from diabetes (e)
and healthy controls (f) after 14 days of culture.
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[46], there appears to be some degree of vascular
damage which is irreversible, even after strict glycemic
control. Additional strategies to further improve the
EPC number and functions in diabetic patients are
required. However, our observations were obtained from
a cross-sectional study, so it should be confirmed in a
cohort study with longitudinal follow-up, to determine
whether strict glycemic control can improve EPC func-
tions and thereby prevent vascular complications.
Conclusion
There was EPC dysfunction in type 2 diabetes which
might be improved by strict glycemic control. The cir-
culating EPC number and proliferative function in
patients with good glycemic control did not reach the
level in healthy controls. However, these observations
obtained from a cross-sectional study should be con-
firmed in a cohort study.
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